Yuce Bio Completes Nearly CNY 100 Million Series A Financing to Build a Closed-Loop Industrial Chain for Clinical Translation of Novel Biomarkers

Recently, Suzhou Yuce Biotechnology Co., Ltd. announced the completion of its nearly RMB 100 million Series A financing round, led by BioTrack Capital and participated by Sinopharm Capital (formerly Guoyao Capital), with continued investment from existing shareholder Puhua Capital and prominent industrial capital investors. This round of financing will support Yuce Biotechnology in building a closed-loop industrial chain for the clinical translation of novel biomarkers, advancing the in-depth development of high-sensitivity biomarker detection technologies and accelerating the clinical translation of new biomarkers.

Yuce Bio’s single-molecule immunoassay technology is backed by fully independent intellectual property rights. Its innovative technical pathway offers advantages of high throughput, strong stability, and ease of mass production, making the clinical translation of single-molecule immunoassay technology feasible. To date, Yuce Bio’s core product line of single-molecule immunoassay instruments comprehensively meets research and clinical needs across semi-automated, fully automated, ultra-sensitive, and high-throughput platforms. Its reagent kit portfolio spans multiple application areas, including neurology, infectious diseases, oncology, cardiac markers, and inflammation, establishing a robust product barrier. Through strategic integration of industrial resources, Yuce Bio has also achieved key upstream layouts in core raw materials and molecular auxiliary diagnostics. Recently, Yuce Bio obtained China’s first medical device approval for a fully automated single-molecule immunoassay diagnostic instrument, signaling that the company has taken a comprehensive lead in this specialized segment of the single-molecule immunoassay field.

Single-molecule immunoassay technology offers a 1,000-fold increase in sensitivity compared to traditional immunoassay techniques and is regarded as the next-generation immunoassay technology following chemiluminescence. This significant enhancement in sensitivity has made it possible to clinically apply nearly a thousand biomarkers that were previously difficult to translate into clinical practice using conventional immunoassay methods. Yuce Biotech, with single-molecule immunoassay technology at its core, is committed to building a complete commercial closed-loop encompassing novel biomarker screening, core raw material development, ultra-sensitive biomarker assay kit development, and clinical translation, thereby advancing the clinical translation and application of ultra-sensitive novel biomarkers.

Li Han, Vice President of Investment at BioTrack Capital, stated:We are delighted to lead the Series A financing round for YuCe Bio. Single-molecule immunoassay technology offers sensitivity far surpassing that of traditional immunoassays, making it a crucial tool for the development and clinical translation of many low-abundance biomarkers. YuCe Bio’s single-molecule immunoassay platform, which possesses fully independent intellectual property rights, fills a gap in China’s ultra-sensitive detection sector. The platform’s ease of use makes it highly suitable for the clinical translation of new biomarkers across multiple diseases and types, including neurodegenerative disorders, ophthalmology, nephrology, and infectious diseases. It is an honor to collaborate with this outstanding team, which combines strong R&D capabilities, vitality, and extensive industry experience. We look forward to YuCe Bio’s continued innovation and its efforts to expand the application of emerging technologies, such as single-molecule immunoassays, in life sciences and clinical diagnostics.

Zou Min, Partner at Sinopharm Capital, stated:Yuce Bio aligns with our investment strategy in the IVD sector, which focuses on “Clinical + Life Science Tools.” Leveraging its innovative single-molecule immunoassay technology, the company has established a leading position in both scientific research and clinical applications. Particularly in the field of neuroscience, Yuce Bio has achieved self-sufficiency and control over upstream antibody raw materials. By integrating these with its molecular diagnostics platform, the company can provide more comprehensive diagnostic solutions for clinical use. We also congratulate Yuce Bio on obtaining regulatory approval for its fully automated single-molecule immunoassay instrument. We are optimistic that its young and dynamic team will continue to achieve breakthroughs in commercialization.

Zhou Mi, Managing Partner at Puhua Capital, stated:Yuce Biotechnology aligns perfectly with our investment philosophy of “translational medicine.” We believe that the core challenge in medical device venture capital lies in the clinical and commercial translation of intellectual property or scientific achievements. The translation of medical devices requires close collaboration among five key stakeholders: industry, academia, research institutions, healthcare providers, and government authorities (“industry-academia-research-clinical practice-government”), with venture capital firms and government agencies serving as crucial driving forces behind this process. Yuce Biotechnology possesses significant advantages through its proprietary single-molecule immunoassay technology and demonstrates strong capabilities in clinical translation. Its novel biomarker translation platform, centered on single-molecule immunoassay technology, holds the potential to facilitate the genuine translation of numerous biomarkers across the “industry-academia-research-clinical practice-government” spectrum. We are delighted to have witnessed the achievements Yuce Biotechnology has made over the past two years, and we sincerely look forward to seeing the company realize substantial commercial value in the clinical translation of biomarkers.

Guan Zhichao, founder of Yuce Biotech, stated:We extend our gratitude to the investors in this round and all shareholders of Yuce Bio for their support. We are fortunate to pursue our ideals of technological innovation and commercial translation in an era that is most conducive to such endeavors. On the path of more specialized and ambitious scientific research and clinical development, we will continue to forge ahead and set sail, striving to become a trusted supporter and leader in the life and health sector.

Suzhou Yuce Biotechnology Co., Ltd. was established in 2019 and operates a R&D and production center spanning nearly 6,000 square meters. As a high-tech enterprise dedicated to the industrialization of single-molecule immunoassay technology, the company holds full independent intellectual property rights for its core technologies, successfully filling a gap at the forefront of this field in China. Guided by the vision of “becoming a trusted supporter and leader in the life and health sector,” and adhering to the mission of “advancing human health through precise diagnostics and creating an infinite future through technological innovation,” the company focuses on single-molecule immunoassay technology. It is committed to the research and development and clinical translation of novel biomarkers, with the potential to drive the next generation of transformative advances in immunoassay technology.

BioTrack Capital, established in 2017, is a professional investment firm dedicated to investing in and incubating outstanding healthcare startups in the Chinese market. Currently, BioTrack Capital manages two RMB funds and two USD funds, with total assets under management exceeding RMB 7 billion. More than just an investor, BioTrack Capital serves as a long-term partner to entrepreneurs. Since its inception, the firm has remained entrepreneur-centric, consistently supporting and empowering exceptional founders in the healthcare sector, fostering an industry ecosystem, and cultivating the next generation of leading enterprises in China’s healthcare industry.

Shanghai Jianyi Private Equity Fund Management Co., Ltd. (formerly Sinopharm Capital) was established in 2012 by the senior management team of the former Sinopharm Group, operating under market-oriented mechanisms. It combines the strategic investment advantages of a Corporate Venture Capital (CVC) with the market-driven strengths of an independent Venture Capital (VC) fund, focusing on early-stage and growth-stage equity investments in the pharmaceutical and healthcare sectors. Leveraging its industrial resources to empower portfolio companies, Jianyi Capital has managed funds exceeding RMB 6.5 billion since its inception. Its investment portfolio comprehensively covers early-stage innovative ventures, growth-stage companies, and M&A integration projects, with investments in more than 80 leading enterprises in the pharmaceutical and healthcare industries. Adhering to the philosophy of “Sincerity, Professionalism, and Win-Win Cooperation,” Jianyi Capital is committed to accompanying its portfolio companies in their shared growth.

Puhua Capital, founded in 2004 and headquartered in Hangzhou, is a professional venture capital and asset management firm with investment offices in Beijing, Shanghai, Shenzhen, and London, UK. Since its inception, Puhua Capital has adhered to its vision of “Embracing a Universal Heart, Pursuing Substantive Excellence,” investing in early-stage and growth-stage innovative startups to help entrepreneurs realize their dreams and generate robust returns for investors. Through years of unwavering commitment, Puhua Capital is proud to have invested in more than 400 outstanding entrepreneurial ventures. The firm remains dedicated, diligent, and insightful, continuing to empower exceptional entrepreneurs and enterprises.